JP7277439B2 - 癌の診断に有用な抗体 - Google Patents

癌の診断に有用な抗体 Download PDF

Info

Publication number
JP7277439B2
JP7277439B2 JP2020513799A JP2020513799A JP7277439B2 JP 7277439 B2 JP7277439 B2 JP 7277439B2 JP 2020513799 A JP2020513799 A JP 2020513799A JP 2020513799 A JP2020513799 A JP 2020513799A JP 7277439 B2 JP7277439 B2 JP 7277439B2
Authority
JP
Japan
Prior art keywords
antibody
seq
amino acid
acid sequence
set forth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020513799A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020532572A5 (cg-RX-API-DMAC10.html
JP2020532572A (ja
Inventor
リタ ミットナハト－クラウス，
シュテファン ウォール，
コルデン ウォルター，
エズレム テューレヒ，
ウグル サヒン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Original Assignee
Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz filed Critical Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Publication of JP2020532572A publication Critical patent/JP2020532572A/ja
Publication of JP2020532572A5 publication Critical patent/JP2020532572A5/ja
Priority to JP2023076556A priority Critical patent/JP7882806B2/ja
Application granted granted Critical
Publication of JP7277439B2 publication Critical patent/JP7277439B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/91—Cell lines ; Processes using cell lines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020513799A 2017-09-06 2018-09-05 癌の診断に有用な抗体 Active JP7277439B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023076556A JP7882806B2 (ja) 2017-09-06 2023-05-08 癌の診断に有用な抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2017/072386 WO2019048040A1 (en) 2017-09-06 2017-09-06 ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER
EPPCT/EP2017/072386 2017-09-06
PCT/EP2018/073883 WO2019048489A1 (en) 2017-09-06 2018-09-05 ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023076556A Division JP7882806B2 (ja) 2017-09-06 2023-05-08 癌の診断に有用な抗体

Publications (3)

Publication Number Publication Date
JP2020532572A JP2020532572A (ja) 2020-11-12
JP2020532572A5 JP2020532572A5 (cg-RX-API-DMAC10.html) 2022-04-27
JP7277439B2 true JP7277439B2 (ja) 2023-05-19

Family

ID=59858709

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020513799A Active JP7277439B2 (ja) 2017-09-06 2018-09-05 癌の診断に有用な抗体
JP2023076556A Active JP7882806B2 (ja) 2017-09-06 2023-05-08 癌の診断に有用な抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023076556A Active JP7882806B2 (ja) 2017-09-06 2023-05-08 癌の診断に有用な抗体

Country Status (15)

Country Link
US (3) US11279757B2 (cg-RX-API-DMAC10.html)
EP (2) EP3679069B1 (cg-RX-API-DMAC10.html)
JP (2) JP7277439B2 (cg-RX-API-DMAC10.html)
KR (2) KR20230107371A (cg-RX-API-DMAC10.html)
CN (3) CN115433283B (cg-RX-API-DMAC10.html)
AU (2) AU2018327587B2 (cg-RX-API-DMAC10.html)
BR (1) BR112020003694B1 (cg-RX-API-DMAC10.html)
CA (1) CA3073157A1 (cg-RX-API-DMAC10.html)
ES (1) ES2998108T3 (cg-RX-API-DMAC10.html)
IL (2) IL293017A (cg-RX-API-DMAC10.html)
MX (2) MX393242B (cg-RX-API-DMAC10.html)
PL (1) PL3679069T3 (cg-RX-API-DMAC10.html)
SG (1) SG11202000961SA (cg-RX-API-DMAC10.html)
WO (2) WO2019048040A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202000851B (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2404936A1 (en) * 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
WO2019048040A1 (en) 2017-09-06 2019-03-14 Ganymed Pharmaceuticals Gmbh ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER
CA3177215C (en) 2017-09-29 2026-06-09 Daiichi Sankyo Company, Limited Antibody-pyrrolobenzodiazepine derivative conjugate
CN119708241A (zh) 2019-02-15 2025-03-28 因特格尔莫来库乐有限公司 密封蛋白6抗体及其用途
IL307744A (en) * 2021-04-22 2023-12-01 Astellas Pharma Inc Anti-CLDN4/anti-CD137 bispecific antibody
JP2025528148A (ja) * 2022-08-09 2025-08-26 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア クローディン－６抗体及びそのコンジュゲート及び使用
CN120282987A (zh) 2022-11-30 2025-07-08 因特格尔莫来库乐有限公司 包括双特异性型式的针对紧密连接蛋白6的抗体
KR20260015262A (ko) 2023-05-25 2026-02-02 더 리전트 오브 더 유니버시티 오브 캘리포니아 암 치료를 위한 클라우딘-6 접합체의 투여량
TW202542202A (zh) * 2024-01-04 2025-11-01 美商翰森生物有限責任公司 抗體、抗原結合片段及其醫療用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
KR100944575B1 (ko) 2002-10-17 2010-02-25 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
AU2004272607B2 (en) * 2003-09-11 2008-11-06 Cornerstone Therapeutics Inc. Monoclonal antibodies against HMGB1
US20100129929A1 (en) * 2006-07-27 2010-05-27 Roberto Polakewicz Tyrosine Phosphorylation Sites
RU2537245C2 (ru) * 2006-10-12 2014-12-27 Чугаи Сейяку Кабусики Кайся Диагностика и лечение злокачественной опухоли с использованием антитела против ereg
WO2009028663A1 (ja) * 2007-08-30 2009-03-05 Kyowa Hakko Kirin Co., Ltd. 抗Claudin-3抗体
AU2009203464A1 (en) * 2008-01-11 2009-07-16 Forerunner Pharma Research Co., Ltd. Anti-CLDN6 antibody
EP3689911B1 (en) * 2009-11-11 2024-08-21 Astellas Pharma Inc. Antibodies specific for claudin 6 (cldn6)
EP2322555A1 (en) * 2009-11-11 2011-05-18 Ganymed Pharmaceuticals AG Antibodies specific for claudin 6 (CLDN6)
EP2404936A1 (en) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
EP3026064B1 (en) * 2011-05-13 2018-10-17 Ganymed Pharmaceuticals GmbH Antibodies for treatment of cancer expressing claudin 6
WO2015014376A1 (en) * 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
GB201607534D0 (en) * 2016-04-29 2016-06-15 Immunocore Ltd & Adaptimmune Ltd Peptides
WO2019048040A1 (en) 2017-09-06 2019-03-14 Ganymed Pharmaceuticals Gmbh ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BMC Cancer，2007年，Vol.7, 196
claudin-6 (A-4): sc-393671，Santa Cruz Biotechnology, Inc.
HEPATOLOGY，2015年，Vol.62, No.4, pp.1059-1069
The Journal of Cell Biology，1999年，Vol.147, No.1, pp.185-194

Also Published As

Publication number Publication date
CA3073157A1 (en) 2019-03-14
AU2018327587B2 (en) 2023-05-04
MX393242B (es) 2025-03-24
BR112020003694A2 (pt) 2020-09-08
PL3679069T3 (pl) 2025-03-24
CN118852435A (zh) 2024-10-29
MX2020002243A (es) 2020-07-20
JP2023103315A (ja) 2023-07-26
SG11202000961SA (en) 2020-02-27
CN115433283A (zh) 2022-12-06
NZ761712A (en) 2025-08-29
AU2023208203A1 (en) 2023-08-17
EP4512830A2 (en) 2025-02-26
EP3679069C0 (en) 2024-11-20
JP2020532572A (ja) 2020-11-12
IL272487A (en) 2020-03-31
IL293017A (en) 2022-07-01
WO2019048040A1 (en) 2019-03-14
EP3679069A1 (en) 2020-07-15
ZA202000851B (en) 2021-08-25
KR20230107371A (ko) 2023-07-14
US20220162302A1 (en) 2022-05-26
BR112020003694B1 (pt) 2024-03-12
US11279757B2 (en) 2022-03-22
AU2018327587A1 (en) 2020-03-05
KR20200040784A (ko) 2020-04-20
EP4512830A3 (en) 2025-05-21
JP7882806B2 (ja) 2026-06-30
WO2019048489A1 (en) 2019-03-14
CN115433283B (zh) 2024-05-24
US11919951B2 (en) 2024-03-05
IL272487B (en) 2022-06-01
US20240209079A1 (en) 2024-06-27
MX2022007706A (es) 2022-07-19
KR102550489B1 (ko) 2023-07-03
EP3679069B1 (en) 2024-11-20
CN111406070A (zh) 2020-07-10
US20200199221A1 (en) 2020-06-25
ES2998108T3 (en) 2025-02-19

Similar Documents

Publication Publication Date Title
US20240309108A1 (en) Antibodies against claudin 18.2 useful in cancer diagnosis
US11919951B2 (en) Antibodies useful in cancer diagnosis
RU2815883C1 (ru) Антитела, пригодные в диагностике рака
HK40085652A (en) Antibodies useful in cancer diagnosis
HK40085652B (en) Antibodies useful in cancer diagnosis
HK40119074A (zh) 用於癌症诊断的抗体
HK40073623A (en) Antibodies against claudin 18.2 useful in cancer diagnosis
HK40077698B (en) Antibodies against claudin 18.2 useful in cancer diagnosis
HK40032868A (en) Antibodies useful in cancer diagnosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200507

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210720

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220419

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220419

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20220419

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220524

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220824

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221004

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230309

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230404

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230508

R150 Certificate of patent or registration of utility model

Ref document number: 7277439

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150